Equities
  • Price (EUR)44.50
  • Today's Change-0.80 / -1.77%
  • Shares traded0.00
  • 1 Year change+25.35%
  • Beta--
Data delayed at least 15 minutes, as of Nov 30 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.

  • Revenue in EUR (TTM)522.03m
  • Net income in EUR50.59m
  • Incorporated1967
  • Employees2.79k
  • Location
    Boiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
  • Phone+33 478456100
  • Fax+33 478456291
  • Websitehttp://www.boiron.fr/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BOI:PAR since
announced
Transaction
value
Abbi SasDeal completed20 Jan 202220 Jan 2022Deal completed24.41%1.98m
Data delayed at least 15 minutes, as of Dec 01 2022 09:27 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.